{"id":"cervarix-glaxosmithkline","safety":{"commonSideEffects":[{"rate":"~78%","effect":"Injection site pain"},{"rate":"~25%","effect":"Injection site redness"},{"rate":"~25%","effect":"Injection site swelling"},{"rate":"~18%","effect":"Fatigue"},{"rate":"~18%","effect":"Myalgia"},{"rate":"~16%","effect":"Headache"},{"rate":"~13%","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cervarix contains virus-like particles (VLPs) derived from the L1 major capsid protein of HPV types 16 and 18, the two strains most commonly associated with cervical cancer. Upon vaccination, the immune system recognizes these particles as foreign antigens and generates a robust humoral and cellular immune response, producing neutralizing antibodies that prevent viral infection of cervical epithelial cells. This prevents the persistent HPV infection that would otherwise lead to precancerous lesions and cervical cancer.","oneSentence":"Cervarix is a bivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 16 and 18, preventing infection and cervical cancer development.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:56.932Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer caused by HPV types 16 and 18"},{"name":"Prevention of cervical intraepithelial neoplasia (CIN) grades 1, 2, and 3 caused by HPV types 16 and 18"}]},"trialDetails":[{"nctId":"NCT03105856","phase":"PHASE4","title":"FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2017-01-03","conditions":"Cervical Intraepithelial Neoplasia, HPV-Related Cervical Carcinoma","enrollment":3000},{"nctId":"NCT03747770","phase":"NA","title":"Effectiveness of Single Dose or Two Doses of Bivalent HPV Vaccine in Thailand","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2018-12-17","conditions":"Healthy","enrollment":18000},{"nctId":"NCT00423046","phase":"PHASE3","title":"Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-24","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":1106},{"nctId":"NCT01101542","phase":"","title":"Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Papillomavirus","enrollment":3091},{"nctId":"NCT00369824","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-26","conditions":"Infections, Papillomavirus","enrollment":1330},{"nctId":"NCT00426361","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-13","conditions":"Infections, Papillomavirus","enrollment":751},{"nctId":"NCT01755689","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-11","conditions":"Infections, Meningococcal","enrollment":1300},{"nctId":"NCT02082639","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2015-02","conditions":"Infections, Papillomavirus","enrollment":""},{"nctId":"NCT02296255","phase":"PHASE4","title":"Effect of HPV Vaccination on Women Aged 25 Years","status":"COMPLETED","sponsor":"Cancer Prevention and Research Institute, Italy","startDate":"2010-04","conditions":"Cervical Cancer","enrollment":832}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":65,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cervarix®, GlaxoSmithKline","genericName":"Cervarix®, GlaxoSmithKline","companyName":"Cancer Prevention and Research Institute, Italy","companyId":"cancer-prevention-and-research-institute-italy","modality":"Biologic","firstApprovalDate":"","aiSummary":"Cervarix is a bivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 16 and 18, preventing infection and cervical cancer development. Used for Prevention of cervical cancer caused by HPV types 16 and 18, Prevention of cervical intraepithelial neoplasia (CIN) grades 1, 2, and 3 caused by HPV types 16 and 18.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}